Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: J Hepatol. 2021 May 28;75(4):888–899. doi: 10.1016/j.jhep.2021.05.018

Figure 7. Combining FAK inhibitor VS-6063 and Palbociclib has potent anti-neoplastic activity in iCCA lesions from Akt/YAP mice.

Figure 7.

(A) Study design. (B) Survival curve, (C) Gross images and H&E, Ki-67, CK19, and C-C-3 staining of livers from pretreatment, vehicle-, VS-6063-, Palbociclib-, and VS-6063/Palbociclib-treated Akt/YAP mice. Asterisks indicate necrotic areas. H&E, CK19: Magnification ×40; scale bar =500μm. Ki-67, C-C-3: Magnification ×200; scale bar =100μm. CK19 positive staining, tumor area on H&E-stained slides, Ki-67, and C-C-3–positive cells were counted and quantified by Image J software. Tukey–Kramer test: at least P < 0.05. a, vs. Pretreatment; b, vs. Vehicle; c, vs. Palbociclib; d, vs. VS-6063. Abbreviations: C-C-3, cleaved caspase 3.